このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Merck マネジメント

マネジメント基準チェック /34

Merck'sの CEO はRob Davisで、 Apr2021年に任命され、の在任期間は 3.17年です。の年間総報酬は$ 20.27Mで、 7.9%給与と92.1%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.014%を直接所有しており、その価値は$ 45.09M 。経営陣と取締役会の平均在任期間はそれぞれ3.2年と4.8年です。

主要情報

Rob Davis

最高経営責任者

US$20.3m

報酬総額

CEO給与比率	7.9%
CEO在任期間	3.2yrs
CEOの所有権	0.01%
経営陣の平均在職期間	3.2yrs
取締役会の平均在任期間	4.8yrs

経営陣の近況

Merck & Co., Inc.'s (NYSE:MRK) CEO Compensation Looks Acceptable To Us And Here's Why

May 22

Recent updates

Dividends And Innovation: Why Merck Is A Healthcare Stock Worth Buying

Jun 10

Merck Stock: Still Discounted To Graham P/E

May 29

Merck & Co., Inc.'s (NYSE:MRK) CEO Compensation Looks Acceptable To Us And Here's Why

May 22

CEO報酬分析

Merck の収益と比較して、Rob Davis の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Mar 31 2024	n/a	n/a	US$2b
Dec 31 2023	US$20m	US$2m	US$365m
Sep 30 2023	n/a	n/a	US$5b
Jun 30 2023	n/a	n/a	US$3b
Mar 31 2023	n/a	n/a	US$13b
Dec 31 2022	US$19m	US$2m	US$15b
Sep 30 2022	n/a	n/a	US$15b
Jun 30 2022	n/a	n/a	US$17b
Mar 31 2022	n/a	n/a	US$14b
Dec 31 2021	US$14m	US$1m	US$12b
Sep 30 2021	n/a	n/a	US$6b
Jun 30 2021	n/a	n/a	US$4b
Mar 31 2021	n/a	n/a	US$5b
Dec 31 2020	US$7m	US$1m	US$5b
Sep 30 2020	n/a	n/a	US$9b
Jun 30 2020	n/a	n/a	US$9b
Mar 31 2020	n/a	n/a	US$9b
Dec 31 2019	US$8m	US$1m	US$6b
Sep 30 2019	n/a	n/a	US$9b
Jun 30 2019	n/a	n/a	US$9b
Mar 31 2019	n/a	n/a	US$8b
Dec 31 2018	US$7m	US$1m	US$6b
Sep 30 2018	n/a	n/a	US$3b
Jun 30 2018	n/a	n/a	US$1b
Mar 31 2018	n/a	n/a	US$2b
Dec 31 2017	US$6m	US$1m	US$2b

報酬と市場: Robの総報酬 ($USD 20.27M ) は、 US市場 ($USD 13.53M ) の同規模の企業の平均を上回っています。

報酬と収益: Robの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Rob Davis (57 yo)

3.2yrs

在職期間

US$20,273,287

報酬

Mr. Robert M. Davis, also known as Rob, J. D., is Chief Executive Officer and Director at Merck & Co., Inc. since July 1, 2021 and is Chairman from December 01, 2022. He serves as President at Merck & Co.,...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Robert Davis	Chairman	3.2yrs	US$20.27m	0.014% $ 45.1m
Caroline Litchfield	Executive VP & CFO	3.2yrs	US$8.30m	0.0020% $ 6.6m
Richard DeLuca	Executive VP & President of Merck Animal Health	12.8yrs	US$6.20m	0.0060% $ 19.6m
Sanat Chattopadhyay	Executive VP & President of Merck Manufacturing Division	14.6yrs	US$6.24m	0.0062% $ 20.4m
Dean Li	Executive VP & President of Merck Research Laboratories	6.6yrs	US$9.78m	0.0018% $ 6.0m
Dalton Smart	Senior VP of Finance	less than a year	データなし	0.00017% $ 557.5k
David Williams	Executive VP and Chief Information & Digital Officer	no data	データなし	0.00078% $ 2.6m
Peter Dannenbaum	Vice President of Investor Relations	4.8yrs	データなし	データなし
Jennifer Zachary	Executive VP & General Counsel	6.2yrs	US$5.90m	0.0011% $ 3.8m
Lisa LeCointe-Cephas	Senior VP and Chief Ethics & Compliance Officer	3.2yrs	データなし	0.00020% $ 655.9k
Cristal Downing	Executive VP and Chief Communications & Public Affairs Officer	2.8yrs	データなし	データなし
Betty Larson	Executive VP & Chief Human Resources Officer	less than a year	データなし	データなし

3.2yrs

平均在職期間

55yo

平均年齢

経験豊富な経営陣: MRKの経営陣は経験豊富であると考えられます ( 3.2年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Robert Davis	Chairman	2.9yrs	US$20.27m	0.014% $ 45.1m
Pamela Craig	Independent Director	8.8yrs	US$400.00k	0.000070% $ 229.6k
Patricia Russo	Independent Director	28.8yrs	US$360.00k	0.00052% $ 1.7m
Thomas Glocer	Independent Lead Director	16.6yrs	US$430.10k	0.00020% $ 655.9k
Risa Lavizzo-Mourey	Independent Director	4.1yrs	US$365.00k	0.000040% $ 131.2k
Douglas Baker	Independent Director	2.1yrs	US$347.64k	0.000040% $ 131.2k
Inge Thulin	Independent Director	6.3yrs	US$340.00k	0% $ 0
Stephen Mayo	Independent Director	3.3yrs	US$350.00k	0% $ 0
Kathy Warden	Independent Director	4.3yrs	US$350.00k	0.000020% $ 65.6k
Christine Seidman	Independent Director	4.3yrs	US$350.00k	0% $ 0
Paul Rothman	Independent Director	8.8yrs	US$380.00k	0% $ 0
Mary Coe	Independent Director	5.3yrs	US$342.36k	0% $ 0

4.8yrs

平均在職期間

65.5yo

平均年齢

経験豊富なボード: MRKの取締役会は経験豊富であると考えられます ( 4.8年の平均在任期間)。

Merck マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Merck & Co., Inc.'s (NYSE:MRK) CEO Compensation Looks Acceptable To Us And Here's Why

Insider exercised options to buy US$1.8m worth of stock.

Merck & Co., Inc., Annual General Meeting, May 28, 2024

Insider notifies of intention to sell stock

Recent updates

Dividends And Innovation: Why Merck Is A Healthcare Stock Worth Buying

Moderna & Merck Announces 3-Year Data for mRNA-4157 (V940) in Combination with KEYTRUDA (Pembrolizumab)

First quarter dividend of US$0.77 announced

Merck & Co., Inc. (NYSE:MRK) entered into a definitive agreement to acquire Eyebiotech Limited for $3 billion.

Merck Declares Dividend for the Third Quarter of 2024, Payable on July 8, 2024

Merck Stock: Still Discounted To Graham P/E

Merck Announces Phase 3 KEYNOTE-522 Trial Met Its Overall Survival (OS) Endpoint in Patients with High-Risk Early-Stage Triple Negative Breast Cancer (TNBC)

Merck & Co., Inc.'s (NYSE:MRK) CEO Compensation Looks Acceptable To Us And Here's Why

Merck Provides Update on Phase 3 KeyVibe-010 Trial Evaluating an Investigational Coformulation of Vibostolimab and Pembrolizumab as Adjuvant Treatment for Patients With Resected High-Risk Melanoma

Merck Provides Update on Phase 3 KEYNOTE-B21 Trial Evaluating KEYTRUDA (pembrolizumab) Plus Chemotherapy

Insider exercised options to buy US$1.8m worth of stock.

Merck Q1: There's Still Room For Growth

Merck Announces Phase 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of Overall Survival as First-Line Treatment in Patients with HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Merck & Co., Inc. Provides Earnings Guidance for Full-Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Merck Earnings Preview: Not Much To Fear, Plenty To Look Forward To

We Think Merck (NYSE:MRK) Can Stay On Top Of Its Debt

Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA®? (pembrolizumab) for First-Line Treatment of Certain Patients with Metastatic Non-Small Cell Lung Cancer

Merck: Better Times Ahead On Approvals And Outlook

European Commission Approves Merck’s Keytruda® (Pembrolizumab) Plus Chemotherapy

Merck's Future Brightens With Winrevair's Blockbuster Potential

Merck Provides Update on Phase 3 Keylynk-006 Trial Evaluating Keytruda® (Pembrolizumab) Plus Maintenance Lynparza® (Olaparib) for Certain Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer

Merck Announces Positive Data on V116, Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults

Merck Announces its KEYTRUDA Plus Chemoradiotherapy (CRT) Significantly Improved Overall Survival Versus CRT Alone in Patients with Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

Merck Announces Plans to Conduct Clinical Trials of A Novel Investigational Multi-Valent Human Papillomavirus (HPV) Vaccine and Single-Dose Regimen for GARDASIL®9

IDEAYA Biosciences, Inc. Announces Clinical Collaboration to Evaluate Ide161 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Endometrial Cancer

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

Upcoming dividend of US$0.77 per share

Merck: A High-Conviction Investment For Long-Term Growth

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment of Resectable NSCLC at High Risk of Recurrence

Merck & Co., Inc., Annual General Meeting, May 28, 2024

FDA Grants Priority Review to Merck's Application for Keytruda (Pembrolizumab) Plus Chemotherapy as Treatment for Primary Advanced or Recurrent Endometrial Carcinoma

Health Canada Approves Keytruda® in Combination with Trastuzumab and Chemotherapy, as A First-Line Treatment for Patients with Locally Advanced Her2-Positive Gastric or Gastric or Gastroesophageal Junction Adenocarcinoma

Insider notifies of intention to sell stock

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /34